"The Changing Landscape of Diagnostic Biomarkers: Exploring the One-biomarker-per-drug Paradigm in Oncology" -
Personalized medicine and immunotherapy are changing the landscape of cancer diagnosis and treatment. Traditionally, the one-biomarker-per-drug model has been driving the development of single companion diagnostic tests to inform patient selection for drug therapy. Importantly, the development of multiple tests for the same biomarker, often for the same indication, has further complicated the analysis. A classic example is the case of PD-L1, for which there are currently five different immunohistochemistry assays for use with five different PD-1/PD-L1 monoclonal antibody therapies. Sacha Gnjatic, PhD, from the Icahn School of Medicine, will discuss PD-L1 as a case study on in a webinar on May 1.
— Sacha Gnjatic, PhD, Associate Director, Human Immune Monitoring Center at Mount Sinai, Associate Professor, Oncological Sciences, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai